Xencor (NASDAQ:XNCR) Hits New 12-Month Low – Time to Sell?

Xencor, Inc. (NASDAQ:XNCR)’s stock price hit a new 52-week low on Monday . The stock traded as low as $13.42 and last traded at $13.60, with a volume of 76991 shares changing hands. The stock had previously closed at $13.87.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. Wells Fargo & Company decreased their target price on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Finally, StockNews.com upgraded shares of Xencor from a “sell” rating to a “hold” rating in a report on Thursday. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Xencor presently has a consensus rating of “Buy” and an average target price of $34.38.

Xencor Trading Down 2.2 %

The firm has a market capitalization of $955.46 million, a P/E ratio of -4.24 and a beta of 0.74. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $18.39 and a 200-day simple moving average of $20.61.

Xencor (NASDAQ:XNCR) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $52.79 million during the quarter, compared to analyst estimates of $17.14 million. On average, equities research analysts forecast that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Hedge Funds Weigh In On Xencor

A number of institutional investors have recently bought and sold shares of the stock. Mackenzie Financial Corp bought a new stake in Xencor during the 4th quarter worth approximately $101,000. GF Fund Management CO. LTD. purchased a new position in shares of Xencor in the fourth quarter valued at about $34,000. Public Employees Retirement System of Ohio purchased a new stake in Xencor during the 4th quarter valued at approximately $1,227,000. Woodline Partners LP raised its position in shares of Xencor by 0.3% during the fourth quarter. Woodline Partners LP now owns 845,916 shares of the biopharmaceutical company’s stock valued at $19,439,000 after buying an additional 2,591 shares during the last quarter. Finally, Teza Capital Management LLC purchased a new position in shares of Xencor in the fourth quarter worth $210,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.